Efficacy and selectivity of nilotinib on NF1-associated tumors in vitro

Journal of Neuro-Oncology

Volumn 116, Issue 2, 2014, Pages 231-236

  Jiang, Wei ^a   Schnabel, Claudia ^a   Spyra, Melanie ^a   Mautner, Victor F ^a   Friedrich, Reinhard E ^a   Hagel, Christian ^a   Manley, Paul W ^b   Kluwe, Lan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Drug selectivity; Malignant peripheral nerve sheath tumors; Neurofibromatosis type 1; Nilotinib; Plexiform neurofibroma

Indexed keywords

COLLAGENASE; NILOTINIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NEUROFIBROMA; NEUROFIBROMATOSIS; SCHWANN CELL;

ANNEXIN A5; ANTIGENS, THY-1; APOPTOSIS; CELL PROLIFERATION; COLLAGENASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; PYRIMIDINES; SCHWANN CELLS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893710766     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1295-z     Document Type: Article

References (17)

1. Demestre M, Herzberg J, Holtkamp N, Hagel C, Reuss D, Friedrich RE, Kluwe L, Von Deimling A, Mautner VF, Kurtz A (2010) Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. J Neurooncol 98:11-19
2. Kim BK, Choi YS, Gwoo S, Park YH, Yang SI, Kim JH (2012) Neurofibromatosis type 1 associated with papillary thyroid carcinoma incidentally detected by thyroid ultrasonography: a case report. J Med Case Rep 6:179
3. Mautner VF, Hartmann M, Kluwe L, Friedrich RE, Funsterer C (2006) MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1. Neuroradiology 48:160-165
4. Spyra M, Kluwe L, Hagel C, Nguyen R, Panse J, Kurtz A, Mautner VF, Rabkin SD, Demestre M (2011) Cancer stem cell-like cells derived from malignant peripheral nerve sheath tumors. PLoS ONE 6:e21099
5. Brems H, Beert E, de Ravel T, Legius E (2009) Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol 10:508-515
6. Robertson KA, Nalepa G, Yang FC, Bowers DC, Ho CY, Hutchins GD, Croop JM, Vik TA, Denne SC, Parada LF, Hingtgen CM, Walsh LE, Yu M, Pradhan KR, Edwards-Brown MK, Cohen MD, Fletcher JW, Travers JB, Staser KW, Lee MW, Sherman MR, Davis CJ, Miller LC, Ingram DA, Clapp DW (2012) Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol 13:1218-1224
7. Frahm S, Mautner VF, Brems H, Legius E, Debiec-Rychter M, Friedrich RE, Knöfel WT, Peiper M, Kluwe L (2004) Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients. Neurobiol Dis 16:85-91
8. Holtkamp N, Okuducu AF, Mucha J, Afanasieva A, Hartmann C, Atallah I, Estevez-Schwarz L, Mawrin C, Friedrich RE, Mautner VF, von Deimling A (2006) Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis 27:664-671
9. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. NEJM 354:2542-2551
10. Tanaka C, Yin OQ, Sethuraman V, Smith T, Wang X, Grouss K, Kantarjian H, Giles F, Ottmann OG, Galitz L, Schran H (2010) Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 87:197-203
11. Manley PW, Stiefl N, Cowan-Jacob SW, Kaufman S, Mestan J, Wartmann M, Wiesmann M, Woodman R, Gallagher N (2010) Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem 18:6977-6986
12. Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, Mestan J, Trappe J, Wartmann M, Fabbro D (2010) Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 1804:445-453
13. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A, Viskochil D (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278:51-57
14. Kluwe L, Friedrich R, Mautner VF (1999) Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma. Genes Chromosom Cancer 24:283-285
15. Serra E, Rosenbaum T, Winner U, Aledo R, Ars E, Estivill X, Lenard HG, Lázaro C (2000) Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum Mol Genet 9:3055-3064
16. Hakoda Y, Ito Y, Nagate A, Minemura K, Utsumi K, Aoshima M, Ohyashiki K (2003) Increased collagenase activity in macrophages from bronchial lavage as a diagnostic marker of non-small cell lung cancer. Thorax 58:122-126
17. Study of tasigna®/nilotinib (AMN107) in neurofibromatosis (NF1) patients with plexiform neurofibromas. http://clinicaltrials.gov/ct2/show/ NCT01275586